Cargando…
Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model
Axitinib is an orally available inhibitor of tyrosine kinases, with high specificity for vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. It is approved for the treatment of advanced renal cell carcinoma and is in phase II clinical trials for recurrent glioblastoma (GBM). GBM is a...
Autores principales: | Merolle, Matilde, Mongiardi, Maria Patrizia, Piras, Maurizia, Levi, Andrea, Falchetti, Maria Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073100/ https://www.ncbi.nlm.nih.gov/pubmed/32098270 http://dx.doi.org/10.3390/ijms21041490 |
Ejemplares similares
-
Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2021) -
c-MYC inhibition impairs hypoxia response in glioblastoma multiforme
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2016) -
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2015) -
Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022) -
Autophagy in homocysteine‑induced HUVEC senescence
por: Zhang, Yexi, et al.
Publicado: (2023)